Navigation Links
Diatos Announces Positive Clinical Results for its DTS-201,Doxorubicin Prodrug Program

out any unexpected side effects," stated Jean-Pierre Delord, M.D., principal investigator from the anti-cancer center Claudius Regaud Institute in Toulouse, France. "In particular, no severe toxicity has been observed even after the administration of six cycles of the agent in this Phase I trial. Furthermore, we have observed some encouraging activity in normally chemo-resistant cancers."

DTS-201 was initially discovered by Pr Andre Trouet and his team at the Universite Catholique de Louvain, Belgium, and exclusive European rights were in-licensed from Medarex Inc. in April 2003 as a preclinical compound.

President and CEO of Diatos John Tchelingerian, Ph.D, added: "I am satisfied that Diatos continues to make substantial progress in its clinical development programs based on novel, targeted anti-cancer chemotherapies. The positive results from our Phase I study with DTS-201, particularly the encouraging signs of improved efficacy versus standard doxorubicin treatment, represent a significant milestone in the development of our product. Diatos is poised to initiate a Phase II study for DTS-201 in Europe soon, advancing what we believe is a next generation anthracycline for the benefit of cancer patients."

Notes to Editors:

About DTS-201

DTS-201 consists of doxorubicin, a marketed cytotoxic agent effective against a wide variety of solid tumors, conjugated to a proprietary peptide. The product was discovered in 1996 by Pr Andre Trouet and his team at the Universite Catholique de Louvain, Belgium and in-licensed from Medarex Inc in April 2003. DTS-201 is also known as Super-Leu-Dox or CPI-0004Na in the USA.

DTS-201 is a prodrug designed to preferentially deliver doxorubicin to tumors as opposed to normal tissues. It consists of the tetrapeptide N-succinyl-(beta)-alanyl-L-leucyl-L-alanyl-L-leucine covalently linked to the aminoglycoside portion of doxorubicin.

Peptide-based targeting of tumors is an attractive approach f
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:3/5/2015)... LAWRENCEVILLE, N.J. , March 5, 2015 /PRNewswire/ ... today that the Company will host a conference ... provide an update on its development programs for ... and two newly acquired technology platforms, TheraPlas™ and ... a.m. ET on Thursday, March 12, 2015. To ...
(Date:3/5/2015)... 05, 2015 Research and Markets ... the "Global Pharma US & EU Outlook ... Major Role In Shaping Up Business for Large ... Strategy Diversification Divested: Productivity measurements, ... position- Will accelerate Next wave of targeted acquisition ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5sqnn3/global_rising ) ... Stars Outlook 2015" report to their offering. ... sought after with fresh vigor as new targets , ... poised to bring a paradigm change in the way ... Stem cell therapy/Regenerative Medicine space. The number ...
Breaking Medicine Technology:Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 2Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 3Global Pharma Rising Stars Outlook 2015 2
... BIOD ) today announced that Dr. Errol De ... the 6th Annual JMP Securities Healthcare Conference at the St. ... Tuesday, September 27, 2011 at 8:30 a.m. ET (5:30 a.m. ... of the presentation, please visit the Investors section of the ...
... Reportlinker.com announces that a new ... its catalogue: Global ... And Packaging: Focus on Emerging Markets ... REPORT HIGHLIGHTS ...
Cached Medicine Technology:Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 2Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 3Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 4Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 5Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 6Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 7Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 8Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 9Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 10Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 11Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 12Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 13Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 14Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 15Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 16Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets 17
(Date:3/5/2015)... March 05, 2015 AxoGen, Inc. ... on the peripheral nerve repair market, reported record revenue ... 31, 2014 compared to $2.98 million in the year-ago ... growth strategies. , “Our strong fourth quarter revenue ... nerve repair products which is driving increased surgeon adoption ...
(Date:3/5/2015)... March 05, 2015 HomeCEUConnection.com ... March with extra savings on their nutrition ... of health and nutrition, HomeCEUConnection.com is offering ... the promo code, NUTRITION2015 . , ... , HomeCEUConnection.com provides high-quality continuing education ...
(Date:3/5/2015)... 05, 2015 TCS Healthcare Technologies (TCS), ... the population health management arena, is pleased to announce ... software, ACUITY Advanced Care™ (ACUITY) version 7.20. The session ... and the advantages of automation. , The webinar, scheduled ... be led by Jeff Frater, RN, BSN, Director of ...
(Date:3/5/2015)... Portland, Ore. (PRWEB) March 05, 2015 ... health sciences university founded in 1904, has launched ... behaviors and positive lifestyle changes. The Northwest Center ... educate health professionals, support community outreach, and conduct ... promotion, functional medicine, diet and nutrition. The center ...
(Date:3/5/2015)... 2015 INTEGRATED Healthcare Strategies, a ... participate in its 2015 Children’s Hospitals Executive Compensation ... director-level positions, and the survey results are exclusive ... featured data on 60 executive and director level ... and 7 subsidiary children’s hospitals. Additionally, it provided ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Participation Is Now Open For INTEGRATED Healthcare Strategies 2015 Children’s Hospitals Executive Compensation Survey 2
... International, Inc.,(Nasdaq: CHDX ), a leading ... in the People,s Republic of China, today announced ... ChinaVenture Investment Conference,2009, to be held at the ... 17. The,Company will conduct meetings with institutional investors ...
... 2009 NORTH HOLLYWOOD, Calif., March 4 IPC The ... leading national hospitalist physician group practice, announced today that ... & Access Method", or "E-Proxy" rules, that allow companies ... as an alternative to the traditional approach of delivering ...
... shed light on physiology of phobias in general, study ... variants that increase cocaine addicts, risk of paranoia have ... of almost 4,000 people of African and European descent, ... team examined an area of the genome previously shown ...
... to anti-nausea drug , , WEDNESDAY, March 4 (HealthDay News) -- ... Wednesday that patients who are injured by a drug can ... has been granted FDA approval. , The decision, in ... to a Vermont musician named Diana Levine who had to ...
... Abbott will present at the Cowen and Company ... Thomas C. Freyman, executive vice president, finance and ... the company at 8:30 a.m. Central time.A live audio ... Investor Relations Web site at www.abbottinvestor.com . ...
... WASHINGTON, March 4 The U.S. Supreme Court in ... Levine, the plaintiff in the Supreme Court case Wyeth v. ... she suffered -- which included the loss of her arm ... the Supreme Court,s majority opinion, Justice John Paul Stevens said ...
Cached Medicine News:Health News:Chindex International, Inc. to Participate in the Piper Jaffray & ChinaVenture Investment Conference 2009 2Health News:IPC The Hospitalist Company Adopts 'E-Proxy' to Reduce Environmental Impact 2Health News:Gene Variant Tied to Cocaine-Induced Paranoia 2Health News:Supreme Court Rejects Limits on Drug-Injury Lawsuits 2Health News:Supreme Court Rejects Limits on Drug-Injury Lawsuits 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: